ConvaTec Group PLC (LON:CTEC) Receives Consensus Recommendation of “Buy” from Analysts

ConvaTec Group PLC (LON:CTEC) has been assigned a consensus rating of “Buy” from the six brokerages that are covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is GBX 307.17 ($3.93).

Separately, Berenberg Bank restated a “buy” rating and issued a GBX 310 ($3.97) price target on shares of ConvaTec Group in a research report on Tuesday, June 11th.

ConvaTec Group Price Performance

CTEC stock opened at GBX 245.40 ($3.14) on Wednesday. The company has a debt-to-equity ratio of 77.53, a current ratio of 1.62 and a quick ratio of 0.96. The business has a 50 day simple moving average of GBX 248.38 and a 200-day simple moving average of GBX 256.45. The firm has a market capitalization of £5.03 billion, a PE ratio of 4,908.00, a price-to-earnings-growth ratio of 2.10 and a beta of 0.60. ConvaTec Group has a 1 year low of GBX 195.10 ($2.50) and a 1 year high of GBX 295.20 ($3.78).

About ConvaTec Group

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns.